Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Gerald Marit"'
Autor:
Bertrand Joly, Hagay Sobol, Isabelle Azais, Hervé Avet-Loiseau, Karine Augeul-Meunier, Catherine Le Bris, Delphine Demangel, Maroulio Pertesi, Xavier Leleu, Maria Victoria Revuelta, Maxime Vallée, Manuel Cliquennois, James D. McKay, Aurore Perrot, Aleksandra Butrym, Matthieu Foll, Björn Nilsson, Javier Oliver, Judit Várkonyi, Emeline Perrial, Xiaomu Wei, Artur Jurczyszyn, Gabriele Buda, Marcin Rymko, Cécile Leyronnas, Robert J. Klein, Elżbieta Iskierka-Jażdżewska, Claire Mathiot, Marzena Wątek, Eric Voog, Olivier Decaux, Florence Desquesnes, Jill Corre, Arnon Nagler, Jean Gabriel Fuzibet, Véronique Dorvaux, Jan Maciej Zaucha, Philippe Rodon, Siwei Chen, Denis Caillot, Laurent Garderet, Michel Maigre, Isabelle Leduc, Fabienne Lesueur, Borhane Slama, Sophie Rigaudeau, Philippe Mineur, Norbert Grząśko, Perrine Galia, Rui Manuel Reis, Federico Canzian, Philippe Helias, Yves-Jean Bignon, Marcin Kruszewski, Victor Moreno, Juan Sainz, Nathalie Cheron, Laurent Voillat, Charles Dumontet, Christian Berthou, Marie Beaumont, Brigitte Pegourie, Etienne Paubelle, Marguerite Vignon, Matteo Pelosini, Philippe Casassus, Isabelle Lambrecht, Laure Vincent, Eileen M Boyle, Annette Juul Vangsted, Pascal Bourquard, Laurent Mosser, Margaret Macro, Gerald Marit, Daniele Campa, Brigitte Kolb, Bruno Royer, Jean Fontan, Ramón García-Sanz, Philippe Moreau, Serge Leyvraz, Malgorzata Krawczyk-Kulis, Krzysztof Jamroziak, Joaquin Martinez-Lopez, Bruno Anglaret, Steven M. Lipkin, Nicole Frenkiel, Ofure Obazee, Marek Dudziński, Pascale Cony-Makhoul, Hervé Naman, Andres Jerez
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, 33 (9), pp.2324-2330. ⟨10.1038/s41375-019-0452-6⟩
Leukemia, Vol. 33, no. 9, p. 2324-2330 (2019)
Dipòsit Digital de la UB
Universidad de Barcelona
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0452-6⟩
Leukemia, 2019, 33 (9), pp.2324-2330. ⟨10.1038/s41375-019-0452-6⟩
Leukemia, vol. 33, no. 9, pp. 2324-2330
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, 33 (9), pp.2324-2330. ⟨10.1038/s41375-019-0452-6⟩
Leukemia, Vol. 33, no. 9, p. 2324-2330 (2019)
Dipòsit Digital de la UB
Universidad de Barcelona
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0452-6⟩
Leukemia, 2019, 33 (9), pp.2324-2330. ⟨10.1038/s41375-019-0452-6⟩
Leukemia, vol. 33, no. 9, pp. 2324-2330
French National Cancer Institute (INCA) and the Fondation Francaise pour la Recherche contre le Myelome et les Gammapathies (FFMRG), the Intergroupe Francophone du Myelome (IFM), NCI R01 NCI CA167824 and a generous donation from Matthew Bell. This wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a993d139f05bf9ec8d952d606cf7f6c
https://hal.univ-brest.fr/hal-02190723
https://hal.univ-brest.fr/hal-02190723
Autor:
Alessandro Corso, Nicolas Leupin, Stoppa Am, Olivier Decaux, Nizar J. Bahlis, Hilde Demuynck, Annette Ervin-Haynes, Miquel Granell, Guang Chen, Shen Zx, Pierre Desjardins, Supratik Basu, Gerald Marit, Lars-Olof Mügge, Thierry Facon, Shang-Yi Huang, Hareth Nahi, T. de Revel, Jennifer Marek
Publikováno v:
15th International Myeloma Workshop
15th International Myeloma Workshop, Sep 2015, Rome, Italy. pp.e56, ⟨10.1016/j.clml.2015.07.196⟩
15th International Myeloma Workshop, Sep 2015, Rome, Italy. pp.e56, ⟨10.1016/j.clml.2015.07.196⟩
e56 Clinica indicated that the classification of UMD/MD was an independent prognosis factor associated with shorter OS. The median OS of UMD underwent bortezomib-based and thalidomide-based therapies were 41.7 and 36.5 months respectively (P1⁄40.60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc73e71db2c5e3cc5280b844db7887f1
https://univ-rennes.hal.science/hal-01228160
https://univ-rennes.hal.science/hal-01228160
Autor:
Loïc Campion, Stephane Minvielle, Jean-Luc Harousseau, Lotfi Benboubker, Philippe Moreau, Marc Wetterwald, Anne-Marie Stoppa, Catherine Guérin-Charbonnel, Denis Caillot, Gerald Marit, Brigitte Kolb, Xavier Leleu, Claire Mathiot, Laurent Voillat, Thierry Facon, Michel Attal, Cyrille Hulin, Hervé Avet-Loiseau, Murielle Roussel, Margaret Macro
Publikováno v:
Journal of Clinical Oncology. 28:4630-4634
Purpose Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that
Autor:
Christian Berthou, Alain Monnereau, F. Huguet, Denis Hémon, Laurent Orsi, Noel Milpied, Pierre Fenaux, Jacqueline Clavel, Gerald Marit, Xavier Troussard, Michel Leporrier, Pierre Soubeyran
Publikováno v:
Cancer Causes & Control. 19:1147-1160
To study potential role of smoking and alcohol in lymphoid neoplasms (LN). A case–control study that included 824 cases and 752 hospital controls aged 18–75 years was conducted. Cases were newly diagnosed with non-Hodgkin’s or Hodgkin’s lymph
Autor:
Edwige Yon, Gerald Marit, Xavier Leleu, Lionel Karlin, Laurent Voillat, Anne-Marie Stoppa, Benjamin Hebraud, Jill Corre, Florence Magrangeas, Laurent Garderet, Alice Cleynen, Cyrille Hulin, Nikhil C. Munshi, Philippe Moreau, Marie-Lorraine Chretien, Hervé Avet-Loiseau, Karim Belhadj, Denis Caillot, Valérie Lauwers-Cances, Stephane Minvielle, Mohamad Mohty, Murielle Roussel, Thierry Facon, Michel Attal, Margaret Macro
Publikováno v:
Blood
Blood, American Society of Hematology, 2015, 125 (13), pp.2095-2100. ⟨10.1182/blood-2014-07-587964⟩
Blood, American Society of Hematology, 2015, 125 (13), pp.2095-2100. ⟨10.1182/blood-2014-07-587964⟩
In multiple myeloma, cytogenetic changes are important predictors of patient outcome. In this setting, the most important changes are deletion 17p, del(17p), and translocation of chromosomes 4 and 14, t(4;14), conferring a poor outcome. However, a ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7497c28baabcd22a7edec441cc0d3e60
https://europepmc.org/articles/PMC4375107/
https://europepmc.org/articles/PMC4375107/
Autor:
Mathieu Molimard, Maria Mamani-Matsuda, Josy Reiffers, Hélène Ferry-Dumazet, M. Diavad Mossalayi, Gerald Marit, Daniel Moynet
Publikováno v:
British Journal of Haematology. 124:141-150
B-cell chronic lymphocytic leukaemia (B-CLL) is a neoplastic disorder characterized by defective apoptosis, cell accumulation in G0/G1, and high expression of BCL2 oncogene. Intracellular cyclic adenosine monophosphate (cAMP) accumulation increases t
Autor:
Marie Parrens, Jean-Michel Boiron, Marie-Edith Lafon, Olivier Hermine, Gerald Marit, Josy Reiffers, Jean-Luc Pellegrin, Jean-François Viallard
Publikováno v:
Clinical Infectious Diseases. 36:229-233
We describe an acromegalic patient who developed a parvovirus B19 (PVB19) infection concomitantly with sarcoidosis, which was complicated by chronic red blood cell aplasia and severe thrombocytopenia, despite disappearance of the virus from serum and
Autor:
Olivier Fitoussi, Chantal Lahet, Marie Hélène Delfau-Larue, Marie Parrens, Pierre Dubus, Gerald Marit, Béatrice Vergier, Geneviève Belleannée, Antoine de Mascarel, Jean-Philippe Merlio
Publikováno v:
The American Journal of Surgical Pathology. 26:1634-1642
We observed in the same patient the development of a tonsil mucosa-associated lymphoid tissue-type lymphoma in 1994, a mediastinal Hodgkin's disease in 1998, and a colonic CD30+ anaplastic diffuse large B-cell lymphoma in 2000. A same-sized FR3-JH fr
Autor:
Odile Maarek, Jean Michel Cayuela, Odile Blanchet, Josy Reiffers, Francois-Xavier Mahon, Eliane Gluckman, Gerald Marit, Delphine Rea, Françoise Huguet, Laurence Legros, Martine Gardembas, Philippe Rousselot
Publikováno v:
Blood. 109:58-60
In the present study, we address the issue of the discontinuation of imatinib mesylate (Gleevec) in chronic myelogenous leukemia with undetectable residual disease for more than 2 years. Twelve patients were included. The median duration of real-time
Publikováno v:
Leukemia. 19:1671-1673
An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate